Notes
Slide Show
Outline
1
 
2
Pump Gasoline?
3
Pump Iron?
4
Pump Breast Milk?
5
THE PANCREAS THROUGHOUT HISTORY
  • 1550 BCE-Papyrus describes polyuria and its treatment
  • 4th century BCE-Ayur Veda of Susruta (India) described sugarcream urine which attracted ants.
  • 7th century CE-Chinese physician Chen Chuan recorded sweet urine in diabetes
  • 1869-Langerhans describes islets
  • 1909-the name insuline is suggested by Jean de Meyer (Brussels)
  • 1921-Banting and Best-report discovering Insulin used in 1922
6
BANTING-1891-1941 & BEST-1899-1978
7
First commercial insulin
8
Prevalence of Diabetes in the US
9
Good Glycemic Control (Lower HbA1c)
Reduces Incidence of Complications
10
HbA1c and Microvascular Complications
11
Every 1% HbA1c Increase Above Goal Elevates the Risk of Diabetic Complications
12
Physiology of Insulin and blood glucose
13
Insulin Preparations
14
NPH and  regular insulin - 2 injections
15
Disadvantages of NPH/ Regular regimen
  • No flexibility:
  • Required certain amount of calories a day
  • Skipped meal - hypoglycemia (peak of NPH)
  • Exercise - hypoglycemia (excessive glucose use)
  • At night - hypoglycemia (peak of NPH)
  • Overeating- hyperglycemia (not enough)
  • Oversleeping- hyperglycemia (skipped dose)


16
Results of conventional therapy
  • Poor control - HbA1C 10% and higher
  • Fear of hypoglycemia - worsening of control
  • Inability to exercise - poor fitness
  • Early development of complications
  • “OUT OF CONTROL”-Negative reinforcement
  • “Don’t Do This, Don’t Do That”
  • Mauriac syndrome - chronic insulin deficiency - stunted growth, hepatomegaly



17
"Some causes of hypoglycemia in..."
  • Some causes of hypoglycemia in toddlers and preschoolers:
    • Unpredictable food intake and physical activity.
    • Imprecise administration of low doses of insulin.
    • Frequent viral infections.
    • Inability to convey the symptoms of low blood sugar.
18
 
19
"IN SEARCH OF THE HOLY..."
  • IN SEARCH OF THE HOLY GRAIL
20
 
21
 
22
Humalog/Novolog versus Regular
  • Rapid acting insulins:               Start in 10min           Peak in 1-2h          Gone in 3.5-4h
  • Regular insulin:    Starts in 30min     Peaks in 3-4h       Gone in 6-8h
23
Benefits of rapid acting insulins
  • May be given just prior to the meal or after meal in babies
  • Time of action match rise in sugar caused by most meals
  • No action left at the time of next meal - no boluses buildups
  • Less activity at bedtime - less night “low’s” and no need for bedtime snack
24
WHEN WE STARTED TO DABBLE-THREE SHOTS A DAY
25
Twice Daily vs. Three Daily Injections
  • Rationale: Avoid Dawn Phenomenon and Somogyi Effect
  • 872 adolescents evaluated over a 3-year period.
  • Either regimen:
    • Increased insulin dose.
    • Deterioration of metabolic control.
    • Increase in BMI.
    • Females faired worse than males.
26
New Long Acting Insulin (Glargine Insulin)
  • Lantus is a new type of long acting insulin that has no peaks
  • Mimics physiological insulin (basal)
27
INSULIN TACTICS
The Basal/Bolus Insulin Concept
  • Basal Insulin
    • Insulin requirement to suppress hepatic glucose production between meals
  • Bolus Insulin (prandial)
    • Insulin requirement to maintain normal glucose disposal after eating
    • Insulin:CHO Ratio = 500/(total starting dose)
    • Correction Factor = 1500/(total starting dose)
    • Correction factor in young children = 1800/(total starting dose)


28
LANTUS AND NOVOLOG-”POOR MANS PUMP”
29
Nine Preschool Patients Meticulously Cared For With MDI Switched To CSII:
  • Mean A1c 9.5% reduced to 7.9%.
    • Severe hypoglycemic events 0.52 per month reduced to 0.09 per month.
    • Increased parental confidence and independence.
    • All refused to relinquish pump at completion of study.
30
Better Control and Less Hypoglycemia in Young Children
31
Glycemic Memory: Sustained Beneficial Effect Of Prior Intensive Therapy

  • 195 patients between the ages of 13 and 17 in DCCT:
    • Decreased worsening of retinopathy by 74% (p < 0.001).
    • Decreased progression to proliferative or severe
      non-proliferative retinopathy by 78% (p < 0.007).
32
Glycemic Memory: Sustained Beneficial Effect Of Prior Intensive Therapy
  • 195 patients between the ages of 13 and 17 in DCCT:
    • Relative risk of hypoglycemia < 1 among prior intensive group.
    • Prevalence of microalbuminuria 48% less.

  • It is vital to achieve the best glycemic control early in the course in diabetes during adolescence and childhood.
33
"“ Less than optimal glycemic..."
  • “ Less than optimal glycemic control during the early years of diabetes has a lasting detrimental effect on the development and progression of complications, even after better glycemic control is established later in the course of the disease.”
34
From Preschool to Prom
  • 161 patients with type 1 diabetes:
    • 26 ages 1 to 6
    • 76 ages 7 to 11
    • 59 ages 12 to 18
  •      98% remained on CSII
  • Reduced hypoglycemia (events/year)
    • Age 1 to 6:  0.42 to 0.19
    • Age 7 to 11:  0.33 to 0.22
    • Age 12 to 18:  0.33 to 0.27

35
World youngest pumper in 1999: 5mo old
36
World youngest pumper 2003: 10 d old
37
I WAS A NON-BELEIVER
  • TOO HARD/TIME CONSUMING
  • I WAS UNINFORMED ON HOW TO USE THEM
  • NOT FOR THE VERY YOUNG OR THE UNMOTIVATED
  • ONLY AFTER HONEYMOON
  • YOU HAVE TO TEST FOR ME TO PUT YOU ON PUMP
  • YOU WILL SUFFER PSYCHOLOGICALLY
38
 
39
Purpose and Method of Study
  • Purpose: compare two algorithms of management for newly diagnosed kids with diabetes in our clinic.


  • Method: A study of HbA1c level and total daily insulin dose in 2 groups of patients with new onset diabetes type 1 at diagnosis, 6 months, and 12th months after diagnosis.


40
Hypothesis
  • Our hypothesis are:
    • Patients on pump have better control of their blood glucose level
    • Better control allows extension of the “honey moon” period
41
Treatment Algorithm
42
HbA1c
43
 
44
 
45
Total daily dose
46
 
47
Conclusion:
  • Intensive teaching, 24 hour support, and CSII within 2 weeks of diagnosis improved patient’s HbA1c levels and decreased total daily dosage of insulin over traditional therapy.
  • CSII was beneficial for newly diagnosed diabetes patients at the onset of disease.
48
Candidates for pump therapy
  • Typical Criteria
  • Only motivated patients
  • only patients who showed good compliance on previous regimen
  • Adults and children > 6y old
  • My Criteria
  • Any patient who is willing to start and has abilities to learn
  • May improve compliance
  • Any age adults and children of any age (independent users 7-80 y old)
  • Particularly “non-compliant” patients
49
ADVERSE EVENTS
50
PSYCHOSOCIAL OUTCOMES
51
The Yale Experience
  • > 200 children started on pumps over last 5 yrs







  • No difference in severe hypoglycemia
  • Parents report less mild hypoglycemia
52
Additional Evidence From Yale
53
CSII vs. MDI With Glargine in Children
54
Pump Group Achieved Better Control Overall
55
More Pump Wearers Achieved HbA1c    6.9%
56
Sweden’s Experience
  • 89 children 3-21 y.o
  • Diabetes duration 6.1 years
  • 30% using CSII
  • HbA1c decreased from 9.2% to 8.4% after CSII start
  • Severe hypos
    • Pump: 11.1/100 pt years
    • MDI: 40.3/100 pt years
57
Patient Characteristics of Successful Pediatric Pumpers
  • Able to maintain follow up appointments with health care provider
  • Willing to record blood glucose values
  • Able to count carbohydrates
  • Good family/social support system
58
Pump therapy benefits
  • Improved control - more physiological basal rates (“dawn phenomenon” match), different boluses for food, less absorption variability
  • Less hypoglycemia
  • More flexible lifestyle and possibility to exercise
  • Precise dosing -  0.1u - 0.025u increments for basal rate and boluses
  • Less injections - improved quality of life
  • Less possibility of overdose
59
Pump Use in Children Is Increasing
  • 200,000 users (adults and kids in the US). 10,000 are adults with type 2 diabetes
  • ~ 20,000 children using pump therapy
    • 10% of all children with diabetes
  • Penetration as high as 90% in some pediatric clinics (ours)
  • Increasing use in younger children (as young as 10 months)
  • Current outcomes indicate CSII is safe and effective in children
  • Increasing acceptance likely due to DCCT findings as well as the introduction of smaller, safer insulin pumps
  • There are approximately 400,000 insulin pump users worldwide
60
Avoiding DKA
  • Give a pen with the pump
  • Instruct that any time the patient feels nauseated or has abdominal pain -- change the site
  • Blood sugar is greater than 250 mg/dl
    • Take correction dose
    • Check for ketones
    • Recheck in 60 minutes
      • If coming down, leave alone
      • If not, take a shot and change the site
61
Summary
  • Pump therapy is an intensive process for pediatric patients and their families and the diabetes education team.
  • Successful pumpers are motivated and willing to maintain follow-up, carbohydrate count, and check blood glucose frequently.
  • Benefits of pump therapy for pediatric patients include:  improved lifestyle, decrease in hypoglycemia, accurate dosing , ability to review history to see if doses were actually given.


62
Summary
  • Children with diabetes should be intensively treated to avoid short and long term complications
  • Insulin pumps can provide better control and less hypoglycemia than MDI
  • With good support and a standardized process, insulin pump therapy can help to improve diabetes management in children
  • Insulin pump therapy should be the only form of therapy offered to children with diabetes
63
When meditating over a disease, I never think of finding a remedy for it, but rather, a means of preventing it.

Louis Pasteur, 1884
64